Related Experiment Videos
Salicylate-induced hepatitis in rheumatic fever
Insights
Salicylate-induced hepatitis occurred in five of 34 children treated for rheumatic fever. Maintaining serum salicylate levels between 15-25 mg/dL is crucial to prevent this adverse effect.
Area of Science:
- Pediatric Rheumatology
- Clinical Toxicology
Background:
- Rheumatic fever is a significant childhood illness requiring anti-inflammatory treatment.
- Salicylates have been a cornerstone in managing rheumatic fever symptoms.
- Previous understanding suggested higher doses were safe for extended periods.
Observation:
- A retrospective analysis of 34 hospitalized children with rheumatic fever treated with salicylates was conducted.
- Five children (14.7%) developed salicylate-induced hepatitis during treatment.
- Serum salicylate levels in affected children averaged 30.9 mg/dL.
Findings:
- Patients who developed hepatotoxicity had significantly higher average serum salicylate levels (30.9 mg/dL) compared to those without (19.7 mg/dL).
- This suggests a threshold for salicylate toxicity exists, even at doses previously considered safe.
- Salicylate-induced hepatitis is a notable complication in pediatric rheumatic fever treatment.
Implications:
- Clinicians should monitor for hepatotoxicity in children receiving salicylates for rheumatic fever.
- Therapeutic drug monitoring of serum salicylate levels is recommended.
- Maintaining serum salicylate levels between 15-25 mg/dL may mitigate the risk of liver injury.
Abstract:
In a 4 1/2-year retrospective study of hospitalized patients with rheumatic fever treated with salicylates, we determined that five of 34 children manifested salicylate-induced hepatitis. The average serum salicylate level in those patients with hepatotoxicity was 30.9 mg/dL, while the average serum salicylate level in the rest of the patients was 19.7 mg/dL. An awareness of this potential complication is important when treating children with salicylates at doses previously considered to be nontoxic. Serum salicylate levels should be maintained at approximately 15 to 25 mg/dL during such therapy.